What Nitric Oxide Does in Blood Vessels
Nitric oxide is a reactive gaseous signalling molecule produced by the enzyme endothelial nitric oxide synthase (eNOS) in the cells lining blood vessels. When eNOS is activated, it converts L-arginine to L-citrulline, releasing NO as a by-product. NO then diffuses into the underlying smooth muscle cells of the vessel wall, binding to guanylate cyclase, which produces cGMP — the second messenger that triggers smooth muscle relaxation.
The result: the blood vessel diameter increases (vasodilation), reducing resistance to blood flow and lowering blood pressure. Endothelial dysfunction — reduced NO production — is one of the earliest markers of cardiovascular disease risk and is strongly associated with hypertension, atherosclerosis, and diabetes. Compounds that restore or augment eNOS activity are therefore of significant therapeutic interest.
🧠 Expert Tip: Why Green Tea Not Black
The eNOS-activating research is predominantly based on EGCG, which is abundant in green but largely converted to theaflavins in black tea. For cardiovascular benefit via the NO pathway, green tea is better supported by the current evidence. Black tea theaflavins have their own separate cardiovascular benefits via antioxidant protection of LDL cholesterol.
The Signalling Cascade: EGCG to eNOS
EGCG has been shown to activate eNOS through a non-receptor-mediated pathway involving the cell membrane. EGCG interacts with membrane lipid rafts and activates the PI3K/Akt signalling cascade — a pathway also activated by insulin. Akt then directly phosphorylates eNOS at Serine 1177, its activation site, causing NO production independent of intracellular calcium concentrations (the classical eNOS activation mechanism).
This explains a critical point: EGCG's cardiovascular effects do not require it to be directly in the blood vessel cells in high concentrations — it needs only to activate surface receptors or membrane pathways at the luminal (blood-facing) surface of endothelial cells. The bioavailability requirements are therefore potentially achievable at the concentrations reached in plasma after drinking 2–3 cups of green tea.
Clinical Evidence: From Cells to People
The laboratory evidence for EGCG-eNOS activation is robust. Clinical evidence is more modest in size but consistent in direction. A 2013 meta-analysis in the European Journal of Nutrition found that green tea consumption was associated with significantly improved flow-mediated dilation (FMD) — the standard clinical measure of endothelial function — with an average improvement of approximately 2–4% absolute FMD. In populations with impaired vascular function, effects were larger than in healthy young subjects.
Blood pressure effects are more variable across trials, but meta-analyses consistently find small but statistically significant reductions: approximately 1.5–3 mmHg systolic and 0.5–1.5 mmHg diastolic with regular green tea consumption over 4–24 weeks. While modest in absolute terms, population-level reductions of this magnitude translate into meaningful cardiovascular risk reduction.
Hibiscus Tea and Nitric Oxide
Separately from Camellia sinensis tea, hibiscus (Hibiscus sabdariffa) anthocyanins have been shown to promote NO production via an antioxidant mechanism — protecting existing NO from free radical destruction rather than stimulating its synthesis. Clinical trials of hibiscus tea consistently show blood pressure reductions of 5–15 mmHg — larger effects than green tea and comparable to some medication classes. See our dedicated hibiscus blood pressure guide for the full evidence review.
Comments